Importance of standardizing renal outcomes in clinical trials: illustration by recent sodium glucose cotransporter 2 inhibitor studies

Daniël H. van Raalte; Petter Bjornstad; Hiddo J. L. Heerspink; Frederik Persson; David Z. I. Cherney

doi:10.1016/j.kint.2020.12.006

Importance of standardizing renal outcomes in clinical trials: illustration by recent sodium glucose cotransporter 2 inhibitor studies

Daniël H. van Raalte^*
, Petter Bjornstad
, Hiddo J. L. Heerspink
, Frederik Persson
, David Z. I. Cherney

^*Corresponding author for this work

University of Colorado Denver
University of Groningen
Steno Diabetes Center
University of Toronto

Research output: Contribution to journal › Letter › Academic › peer-review

Original language	English
Pages (from-to)	768-770
Number of pages	3
Journal	Kidney international
Volume	99
Issue number	3
DOIs	https://doi.org/10.1016/j.kint.2020.12.006
Publication status	Published - 1 Mar 2021

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Access to Document

10.1016/j.kint.2020.12.006

Cite this

@article{44cbfad19fb74bdaa2f4c672bda670b2,

title = "Importance of standardizing renal outcomes in clinical trials: illustration by recent sodium glucose cotransporter 2 inhibitor studies",

author = "\{van Raalte\}, \{Dani{\"e}l H.\} and Petter Bjornstad and Heerspink, \{Hiddo J. L.\} and Frederik Persson and Cherney, \{David Z. I.\}",

note = "Funding Information: DHvR has acted as a consultant and received honoraria from Boehringer Ingelheim and Lilly, Merck, Novo Nordisk, Sanofi, and AstraZeneca and has received research operating funds from Boehringer Ingelheim-Lilly Diabetes Alliance, AstraZeneca, and Novo Nordisk; all honoraria are paid to his employer (AUMC, location VUMC). PB reports grants, personal fees, and nonfinancial support from AstraZeneca; personal fees from Bayer; personal fees from Bristol Meyer Squibb; grants and personal fees from Boehringer-Ingelheim; personal fees from Eli-Lilly; grants and personal fees from Novo Nordisk; personal fees and nonfinancial support from Sanofi; personal fees from XORT; and grants and personal fees from Horizon Pharma, all outside the submitted work. HJLH is a consultant for AbbVie, AstraZeneca, Bayer, Boehringer Ingelheim, Chinook, CSL Pharma, Gilead, Janssen, Merck, Mundi Pharma, Mitsubishi Tanabe, Novo Nordisk, and Retrophin; he has received research support from Abbvie, AstraZeneca, Boehringer Ingelheim, and Janssen. FP reports grants, personal fees, and nonfinancial support from Astra Zeneca; grants, personal fees, and nonfinancial support from Novo Nordisk; personal fees from Boehringer Ingelheim; grants and personal fees from Amgen; personal fees from Novartis; personal fees from MSD; personal fees from Sanofi; personal fees from Eli Lilly; and personal fees from Bayer, all outside the submitted work. DZIC has received honoraria from Boehringer Ingelheim-Lilly, Merck, AstraZeneca, Sanofi, Mitsubishi-Tanabe, Abbvie, Janssen, Bayer, Prometic, BMS, Maze, and Novo-Nordisk and has received operational funding for clinical trials from Boehringer Ingelheim-Lilly, Merck, Janssen, Sanofi, AstraZeneca, and Novo-Nordisk. Copyright: Copyright 2021 Elsevier B.V., All rights reserved.",

year = "2021",

month = mar,

day = "1",

doi = "10.1016/j.kint.2020.12.006",

language = "English",

volume = "99",

pages = "768--770",

journal = "Kidney international",

issn = "0085-2538",

publisher = "Nature Publishing Group",

number = "3",

}

TY - JOUR

T1 - Importance of standardizing renal outcomes in clinical trials: illustration by recent sodium glucose cotransporter 2 inhibitor studies

AU - van Raalte, Daniël H.

AU - Bjornstad, Petter

AU - Heerspink, Hiddo J. L.

AU - Persson, Frederik

AU - Cherney, David Z. I.

N1 - Funding Information: DHvR has acted as a consultant and received honoraria from Boehringer Ingelheim and Lilly, Merck, Novo Nordisk, Sanofi, and AstraZeneca and has received research operating funds from Boehringer Ingelheim-Lilly Diabetes Alliance, AstraZeneca, and Novo Nordisk; all honoraria are paid to his employer (AUMC, location VUMC). PB reports grants, personal fees, and nonfinancial support from AstraZeneca; personal fees from Bayer; personal fees from Bristol Meyer Squibb; grants and personal fees from Boehringer-Ingelheim; personal fees from Eli-Lilly; grants and personal fees from Novo Nordisk; personal fees and nonfinancial support from Sanofi; personal fees from XORT; and grants and personal fees from Horizon Pharma, all outside the submitted work. HJLH is a consultant for AbbVie, AstraZeneca, Bayer, Boehringer Ingelheim, Chinook, CSL Pharma, Gilead, Janssen, Merck, Mundi Pharma, Mitsubishi Tanabe, Novo Nordisk, and Retrophin; he has received research support from Abbvie, AstraZeneca, Boehringer Ingelheim, and Janssen. FP reports grants, personal fees, and nonfinancial support from Astra Zeneca; grants, personal fees, and nonfinancial support from Novo Nordisk; personal fees from Boehringer Ingelheim; grants and personal fees from Amgen; personal fees from Novartis; personal fees from MSD; personal fees from Sanofi; personal fees from Eli Lilly; and personal fees from Bayer, all outside the submitted work. DZIC has received honoraria from Boehringer Ingelheim-Lilly, Merck, AstraZeneca, Sanofi, Mitsubishi-Tanabe, Abbvie, Janssen, Bayer, Prometic, BMS, Maze, and Novo-Nordisk and has received operational funding for clinical trials from Boehringer Ingelheim-Lilly, Merck, Janssen, Sanofi, AstraZeneca, and Novo-Nordisk. Copyright: Copyright 2021 Elsevier B.V., All rights reserved.

PY - 2021/3/1

Y1 - 2021/3/1

UR - https://www.scopus.com/pages/publications/85101099327

U2 - 10.1016/j.kint.2020.12.006

DO - 10.1016/j.kint.2020.12.006

M3 - Letter

C2 - 33637205

SN - 0085-2538

VL - 99

SP - 768

EP - 770

JO - Kidney international

JF - Kidney international

IS - 3

ER -

Importance of standardizing renal outcomes in clinical trials: illustration by recent sodium glucose cotransporter 2 inhibitor studies

UN SDGs

Access to Document

Other files and links

Cite this